Evexia Complete Weight Management Panel

Overview:

The Evexia Diagnostics Complete Weight Management Panel can identify individuals with insulin resistance, prediabetes, metabolic syndrome, and cardiovascular disease risk. Earlier recognition of risk, including hidden risk, means earlier intervention to stop or delay the progression to diabetes before it becomes more complex to manage.

Being overweight or obese is strongly associated with type 2 diabetes, hypertension, and cardiovascular disease. Recent studies have suggested that adipose tissue may play a critical role in developing these conditions and their complications through the secretion of various bioactive molecules referred to as adipokines. Particular to this panel are the analytes adiponectin and leptin. 

Adiponectin may have relevance for energy metabolism through the regulation of fatty acid oxidation. Diminished adiponectin levels have been associated with the increased prevalence of obesity-linked cardiovascular diseases, including ischemic heart disease and peripheral artery disease. 

Leptin is produced primarily by white adipose tissue and blood levels correlated with body fat stores. Increased leptin levels stimulate the central nervous system to reduce appetite and increase energy expenditure. Leptin is thought to play a vital role in the body’s response to food deprivation or starvation. Obesity is most commonly associated with elevated leptin levels. This increase is thought to be due to a resistance to leptin, similar to insulin resistance often seen with obesity.

This panel includes the standard tests such as the complete blood count, comprehensive metabolic panel, a thyroid profile, an iron panel, and a comprehensive urinalysis. This panel also includes the inflammatory biomarker, high-sensitivity C-reactive protein, and both serum and RBC magnesium. Blood glucose dysregulation, common in overweight and obese individuals, is frequently associated with extracellular and intracellular magnesium deficits. This test takes a look at the intracellular level of magnesium. A chronic latent magnesium deficit or overt clinical hypomagnesemia is common in patients with type 2 diabetes, especially in those with poorly controlled glycemic profiles. Insulin and glucose are essential regulators of magnesium metabolism, and intracellular magnesium plays a crucial role in regulating insulin action, insulin-mediated-glucose-uptake, and vascular tone.

Fasting glucose (included in the CMP), along with the biomarker hemoglobin A1c, provides insightful information about glucose metabolism and, when abnormal, can be an indicator of prediabetes, insulin resistance, or diabetes. The A1c test evaluates the average amount of glucose in the blood over the last 2 to 3 months by measuring the percentage of glycated hemoglobin in the blood. The estimated average glucose converts the patient’s HbA1c percentage point into an average blood glucose level. Like HbA1c, eAG (estimated Average Glucose) evaluates a patient’s overall success at controlling glucose levels and helps patients understand the monitoring of their long-term treatment. It’s important to note that blood glucose dysregulation is related to metabolic syndrome, obesity, inflammation, and oxidative stress.

This panel comes with a free* Functional Health Report when Evexia Nutraceuticals are recommended.

*A $5 fee is applied when recommendations other than Evexia Nutraceuticals are selected.